Drug intelligence / Profile preview

QLC5513 + iparomlimab + tuvonralimab + platinum

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

QLC5513 + iparomlimab + tuvonralimab + platinum is an investigational combination therapy regimen developed by Qilu Pharmaceutical for the treatment of advanced or metastatic solid tumors. The regimen consists of QLC5513, an investigational compound, combined with QL1706 (a bifunctional antibody mixture of the anti-PD-1 antibody iparomlimab and the anti-CTLA-4 antibody tuvonralimab) and platinum-based chemotherapy (cisplatin or carboplatin). This combination therapy is designed to provide a multi-pronged attack on cancer cells by combining dual immune checkpoint blockade with the cytotoxic effects of platinum agents. It is currently being evaluated in a Phase Ib/II clinical trial (NCT07272590) to determine the recommended Phase 2 dose and evaluate the objective response rate in patients with advanced malignancies.

Other names: QLC5513 + QL1706 + platinumQLC5513 + iparomlimab + tuvonralimab + cisplatinQLC5513 + iparomlimab + tuvonralimab + carboplatinQLC5513 + epalolimab + tovolimab + platinum

Targets

PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA

Beyond the preview

Go deeper on QLC5513 + iparomlimab + tuvonralimab + platinum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLC5513 + iparomlimab + tuvonralimab + platinum.

Explore the full profile